Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMP16 for Weight Loss in Overweight or Obesity
NCT05934110Phase 2Active, not recruiting
- Sponsor
- Empros Pharma
- Start
- Apr 2023
- Primary completion
- Nov 2023
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of EMP16 in obesity, Overweight, sponsored by Empros Pharma. Started Apr 2023; status: active, not recruiting.
02
Drugs
EMP16
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05934110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934110.